[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Introducing Idiopathic Normal Pressure Hydrocephalus (iNPH), a Form of Dementia That Can Improve With Treatment” (April 11, 2023)
date : 4/26/2023
Tags: Dementia, Diet Member Briefing
Health and Global Policy Institute (HGPI) hosted an installment of 30-minute Health Policy Update, a series of briefings for Diet Members on key health policy issues. This installment was titled, “Introducing Idiopathic Normal Pressure Hydrocephalus (iNPH), a Form of Dementia That Can Improve With Treatment.”
The study session featured a lecture from Professor Hiroaki Kazui (Professor, Department of Neuropsychiatry, Kochi Medical School; Chairman, The Japanese Society of NPH) which provided an explanation of the current circumstances and issues for iNPH, a condition viewed as a form of dementia that can be treated.
A lively exchange of opinions was held with those in attendance during the question and answer session following the lecture.
<Key points of the lecture>
- It is important to diagnose dementia early and provide treatments that are based on its underlying causes. Diagnosis must be performed from the two perspectives of disease prevalence and treatability. It is particularly important that a treatable form of dementia called idiopathic Normal Pressure Hydrocephalus (iNPH) does not go overlooked.
- Normal Pressure Hydrocephalus (NPH) is a disease that presents the triad symptoms of cognitive impairment, gait disturbance, and urinary incontinence. While cerebrospinal fluid (CSF) pressure is within normal range, people with NPH have excessive intracranial CSF build-up and enlarged ventricles. All three symptoms of NPH improve with shunt surgery, so it is now the subject of attention as a treatable form of dementia. iNPH is a form of NPH that appears and progresses gradually and has no known underlying causes. iNPH is often mistaken for Alzheimer’s disease or other changes caused by aging, which sometimes delays diagnosis and treatment.
- The Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition) categorizes diagnostic criteria for iNPH in four stages. Among these stages, it is particularly important to diagnose “Probable iNPH” so shunt surgery can be considered. “Probable iNPH” refers to cases in which patients’ symptoms improve after undergoing a CSF tap test and/or drainage test, or in which they exhibit gait disturbance and their neuroimaging features include narrowing of the sulci and subarachnoid space over the high-convexity/midline surface (known as Disproportionately Enlarged Subarachnoid-Space Hydrocephalus, or DESH). iNPH with DESH has a high improvement rate with shunt surgery.
- Previous studies have shown that the milder the impairments caused by the triad symptoms are before shunt surgery, the more relief of objective symptoms patients experience after surgery. This is why it is considered best to perform shunt surgery for patients with iNPH during the early stages to ensure they can live independently after the procedure. Doing so is also considered important for lightening the burden of providing long-term care that is placed on their family members. However, when iNPH is comorbid with Alzheimer’s disease, other forms of dementia, or other diseases, it may be impossible for patients to receive the full benefits of shunt surgery. This means diagnosing comorbid conditions is as important as differential diagnosis.
- Future challenges for iNPH include promoting early diagnosis, increasing the number of centers that can perform shunt procedures, conducting surveys to grasp real-world conditions surrounding the prevalence of iNPH and its treatment, and establishing a sufficient healthcare provision system. Although an increasing number of health institutions are beginning to treat iNPH, there are still many that specialize in dementia but do not treat iNPH. In addition to the conventional approach in which iNPH is treated as a neurosurgical disease, we must also improve the healthcare provision system from the perspective of dementia and implement the necessary measures for making those improvements. Furthermore, while building a system for closer cooperation among physicians specializing in internal medicine who provide differential diagnosis for iNPH and diagnose comorbid diseases and neurosurgeons who perform shunt procedures, it will also be necessary to broadly disseminate information that will be useful for diagnosing and treating iNPH and DESH, including the aforementioned Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus.
[Program] (Titles omitted)
16:30-16:35 Welcoming Remarks and Explanatory Introduction
Shunichiro Kurita (Senior Manager, Health and Global Policy Institute)
16:35-16:40 Greetings
Hayato Suzuki (Member, House of Representatives; Secretary-General, Parliamentary Association for Promoting Dementia Policies for an Inclusive Society; Special Advisor, Project for iNPH Countermeasures, HGPI)
16:40-17:10 Lecture: Introducing Idiopathic Normal Pressure Hydrocephalus (iNPH) – An Overview of a Form of Dementia That Can Improve With Treatment and Issues in this Area
Hiroaki Kazui (Professor, Department of Neuropsychiatry, Kochi Medical School; Chairman, The Japanese Society of NPH)
17:10-17:30 Question and answer session
Top Research & Recommendations Posts
- [Survey Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Preliminary Version) (September 11, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Achieving Equity in Multidisciplinary Pain Treatment and Support Systems for Pain Management (March 31, 2023)
- [Policy Recommendations] Three Necessary Perspectives for Formulating the Basic Plan for the Promotion of Policies on Dementia: Creating a Society That is Inclusive for All People at All Times (April 1, 2024)
- [New Report] Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era (February 24, 2021)
Featured Posts
-
2024-09-26
[Registration Open] HGPI Salon Special Edition “The 2024 U.S. Presidential Election’s Impact on Japan’s Healthcare Policies: Future Implications for U.S.-China Relations and U.S.-Japan Cooperation” (October 28, 2024)
-
2024-10-07
[Registration Open] International Dialogue “Fostering Community and Citizen-led Approaches to AMR: Lessons from Antibiotic Smart Sweden” (October 25, 2024)
-
2024-10-07
[Registration Open] Planetary Health Expert Meeting “Building the Future of Healthcare: A Vision for Sustainable and Resilient Health Systems with GGHH” (November 5, 2024)
-
2024-10-09
[Registration Open] HGPI Salon Special Edition “Overcoming Infectious Diseases through Partnership: Focusing on examples of promoting technology transfer of antimicrobial agents” (October 21, 2024)
-
2024-10-09
[Registration Open] (Webinar) The 128th HGPI Seminar “Viewing Healthcare Disparities Through the Lens of Breast Cancer Treatment” (October 29, 2024)